Related Experiment Video
Updated: Jun 17, 2026

In Vivo Quantitative Assessment of Myocardial Structure, Function, Perfusion and Viability Using Cardiac Micro-computed Tomography
Published on: February 16, 2016
Choice of contrast medium in patients with impaired renal function undergoing percutaneous coronary intervention
Rainer Wessely1, Tobias Koppara, Christian Bradaric
1Deutsches Herzzentrum and 1 Medizinische Klinik, Klinikum rechts der Isar, Technische Universität, Munich, Germany. rwessely@web.de
Insights
This study found no significant difference in contrast-mediated nephrotoxicity between iso-osmolar and low-osmolar contrast media in patients with chronic renal failure undergoing percutaneous coronary intervention (PCI). However, iodixanol showed potential benefits with higher contrast volumes.
Area of Science:
- Nephrology
- Cardiology
- Radiology
Background:
- Contrast-mediated nephrotoxicity is a concern in patients with chronic renal failure undergoing percutaneous coronary intervention (PCI).
- No prior clinical trials exclusively focused on this high-risk population.
Purpose of the Study:
- To compare the incidence of contrast-mediated nephrotoxicity between iso-osmolar (iodixanol) and low-osmolar (iomeprol) contrast media.
- To evaluate the safety of contemporary contrast media in patients with chronic renal failure undergoing PCI.
Main Methods:
- A prospective, randomized, double-blind, comparative clinical trial.
- 939 patients with chronic renal failure undergoing coronary angiography with potential PCI were randomized.
- 324 patients undergoing PCI were analyzed, receiving either iodixanol or iomeprol.
Main Results:
- The peak increase in serum creatinine after PCI was not significantly different between iodixanol and iomeprol groups (P=0.53).
- Contrast media-induced nephropathy rates were 22.2% for iodixanol and 27.8% for iomeprol, a non-significant difference (P=0.25).
- Subgroup analysis indicated a potential benefit of iodixanol in patients receiving higher contrast volumes (>340 mL) (P(interaction)=0.016).
Conclusions:
- Routine use of iso-osmolar contrast media (iodixanol) does not significantly reduce nephrotoxicity compared to low-osmolar media (iomeprol) in this patient group.
- A potential favorable effect of iodixanol was observed in patients receiving high contrast volumes, warranting further investigation.
- Further randomized trials are needed to confirm these findings.
Background:
No clinical trial has yet focused on contrast-mediated nephrotoxicity in patients with chronic renal failure exclusively undergoing percutaneous coronary intervention (PCI). Therefore, the aim of this study was to compare the effect of contemporary contrast media on nephrotoxicity in this high-risk patient population.
Methods And Results:
This prospective, randomized, double-blind, comparative clinical trial randomly selected 939 patients with chronic renal failure undergoing coronary angiography with potential PCI to receive either the iso-osmolar contrast medium iodixanol or the low-osmolar contrast medium iomeprol. Of those 939 patients, 615 received diagnostic angiography only and were not included in the primary study analysis, but were followed up in a registry. Three hundred twenty-four patients underwent PCI, of which one-half received iodixanol or iomeprol, respectively, and were included in the primary study analysis. The primary end point was the peak increase in S-creatinine during hospitalization for PCI. Maximum increase in S-creatinine after PCI was lower than expected and thus impaired the power of the study. It was not significantly different between the 2 contrast groups (0.19+/-0.40 mg/dL for iodixanol and 0.21+/-0.34 mg/dL for iomeprol; P=0.53). Albeit contrast media-induced nephropathy rates were lower with iodixanol (22.2% compared with 27.8% for iomeprol), this difference was not statistically different (P=0.25). Subgroup analysis suggested a favorable outcome regarding nephrotoxicity in patients who received higher contrast volumes (>340 mL) in the iodixanol group (P(interaction)=0.016).
Conclusions:
Routine use of iso-osmolar contrast medium is not associated with a significant reduction of nephrotoxicity compared with low-osmolar contrast medium in patients with chronic renal failure undergoing PCI. However, a positive effect was seen in the iso-osmolar contrast group for patients receiving high amounts of contrast medium, which awaits confirmation of a specifically designed randomized clinical trial. Clinical Trial Registration- clinicaltrials.gov Identifier: NCT00390585.
Related Concept Videos
Radiological Investigation I: X-ray and CT
Imaging Studies VII: Vascular Imaging
Imaging Studies III: Computed Tomography
Imaging Studies for Cardiovascular System V: CT
Cardiac Catheterization I: Pre-Procedure Overview
Cardiac Catheterization IV: Nursing Management

